5 Key Takeaways

• 1

  The FDA has approved suzetrigine, the first non-opioid analgesic for acute pain management, developed by Vertex Pharmaceuticals.

• 2

  Suzetrigine is a selective NaV1.8 inhibitor, providing an alternative to opioid-based pain management.

• 3

  In phase III trials, suzetrigine showed significant pain reduction compared to placebo but did not outperform hydrocodone/acetaminophen.

• 4

  Common side effects of suzetrigine included mild to moderate nausea, headache, and dizziness.

• 5

  Vertex plans to launch suzetrigine later this year, responding to the demand for non-opioid pain management strategies.